Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0K4NZ
|
|||
Former ID |
DCL001251
|
|||
Drug Name |
Velneperit
|
|||
Synonyms |
Velneperit; 342577-38-2; S-2367; UNII-09BQ2KJ22J; 09BQ2KJ22J; Velneperit [USAN:INN]; Velneperit (USAN/INN); SCHEMBL2806595; SCHEMBL13204979; SCHEMBL10114559; CHEMBL2016681; SCHEMBL10134095; BCP16623; BDBM50380914; AKOS027338754; ZINC257354192; DB12889; CS-5388; KB-81432; HY-14423; BC282913; D08026; 577V382; S-2367;S2367;S 2367; trans-4-(((1,1-Dimethylethyl)sulfonyl)amino)-N-(5-(trifluoromethyl)pyridin-2-yl)cyclohexanecarboxamide; Cyclohexanecarboxamide, 4-(((1,1-dimethylethyl)sulfonyl)amino)-N-(5-(trifluoromethyl)-2-pyridinyl)-, tr
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Discontinued in Phase 2 | [1] | |
Company |
Shionogi & Co Ltd
|
|||
Structure |
Download2D MOL |
|||
Formula |
C17H24F3N3O3S
|
|||
Canonical SMILES |
CC(C)(C)S(=O)(=O)NC1CCC(CC1)C(=O)NC2=NC=C(C=C2)C(F)(F)F
|
|||
InChI |
1S/C17H24F3N3O3S/c1-16(2,3)27(25,26)23-13-7-4-11(5-8-13)15(24)22-14-9-6-12(10-21-14)17(18,19)20/h6,9-11,13,23H,4-5,7-8H2,1-3H3,(H,21,22,24)
|
|||
InChIKey |
WGEWUYACXPEFPO-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 342577-38-2
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neuropeptide Y receptor type 5 (NPY5R) | Target Info | Antagonist | [2] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76. | |||
REF 2 | Clinical pipeline report, company report or official report of Shionogi (2011). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.